The UvA-LINKER will give you a range of other options to find the full text of a publication (including a direct link to the full-text if it is located on another database on the internet).
De UvA-LINKER biedt mogelijkheden om een publicatie elders te vinden (inclusief een directe link naar de publicatie online als deze beschikbaar is in een database op het internet).
faculty: "FNWI" and publication year: "2009"
| Authors||R.G. Boot, M.J. van Breemen, W. Wegdam, R.R. Sprenger, S. de Jong, D. Speijer, C.E.M. Hollak, L. van Dussen, H.C.J. Hoefsloot, A.K. Smilde, C.G. de Koster, J.P.C. Vissers, J.M.F.G. Aerts|
|Title||Gaucher disease: a model disorder for biomarker discovery|
|Journal||Expert Review of Proteomics|
|Faculty||Faculty of Science|
|Institute/dept.||FNWI: Swammerdam Institute for Life Sciences (SILS)|
|Abstract||Gaucher disease is an inherited lysosomal storage disorder, characterized by massive accumulation of glucosylceramide-laden macrophages in the spleen, liver and bone marrow as a consequence of deficient activity of glucocerebrosidase. Gaucher disease has been the playground to develop new therapeutic interventions such as enzyme-replacement therapy and substrate-reduction therapy. The availability of these costly therapies has stimulated research regarding suitable biomarkers to monitor onset and progression of disease, as well as the efficacy of therapeutic intervention. Given the important role of storage cells in the pathology, various attempts have been made to identify proteins in plasma or serum reflecting the body burden of these pathological cells. In this review, the existing data regarding biomarkers for Gaucher disease, as well as the current application of biomarkers in clinical management of Gaucher patients are discussed. Moreover, the use of several modern proteomic technologies for the identification of Gaucher biomarkers is reviewed.|
Use this url to link to this page: http://dare.uva.nl/en/record/360189
Contact us about this recordNotify a colleague
Add to bookbag